Association of opioid receptor mu 1 (OPRM1) A118G polymorphism (rs1799971) with nicotine dependence

Abstract

Background and ObjectWhether opioid-receptor mu 1 (OPRM1) A118G polymorphism (rs1799971) is associated with nicotine dependence is controversial. We analyzed the combined results from published studies of this possibility.MethodsLiterature reviews were performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Web of Science, Chinese National Science Infrastructure (CNKI), PubMed, Embase and Google Scholar database searches using MeSH terms were conducted to find all relevant researches up to October 2016. Odds ratios (ORs) and their 95% confidence intervals (95% CIs) were calculated in allele, homozygote, heterozygote, dominant and recessive models. Ethnicity-specific subgroup meta-analysis, heterogeneity, sensitivity analysis and publication bias were considered.ResultsSeven eligible studies with 3313 patients were included. The ORs in the five genetic models mentioned above were 1.000 (95% CI: 0.906, 1.104; p = 0.999), 1.032 (95% CI: 0.771, 1.381; p = 0.834), 0.963 (95% CI: 0.799, 1.162; p = 0.696), 1.006 (95% CI: 0.916, 1.104; p = 0.907), 0.967 (95% CI: 0.715, 1.309; p = 0.830), respectively. Only in dominant model is the association significant. Upon ethnicity-specific subgroup analysis, there is no statistical significance.ConclusionOPRM1-A118G polymorphism (A>G) is not associated with nicotine dependence.

Is OPRM1 genotype a valuable predictor of VAS in patients undergoing laparoscopic radical resection of colorectal cancer with fentanyl?

“…In addition, in our study, we also found that the amount of fentanyl used by A gene carriers in PACU was significantly higher than that of GG patients. This may be due to the phenotypic effect of the substitution of guanylate G for adenylate A in A118G homozygous mutation patients, which further enhances the endogenous opioid system activity of mutant individuals, thereby reducing their sense of pain [ 17 ]. Molecular-level research [ 18 , 19 ] also shows that the activity of the endogenous opioid system of mutant individuals is enhanced, as is the effect of endogenous opioid substances.…”

Progress, Challenges, and Prospects of Research on the Effect of Gene Polymorphisms on Adverse Reactions to Opioids

“…It is suggested that polymorphisms of the l-opioid receptor can affect the occurrence of PONV, thus affecting the choice of anesthesia method and improving the anesthesia experience of patients. Kong et al [61] showed in the latest meta-analysis of the relationship between OPRM1 and PONV that the A118G polymorphism (rs1799971) may be associated with postoperative vomiting, but not with nausea, itching, or dizziness. The contradictions in these studies suggest that larger, well-designed studies with greater ethnic variation are required to validate the association between OPRM1 and PONV.…”

“…The incidence of PONV was higher in patients with AAG deletion in the two alleles of the 5-HT3B receptor gene [61] lncRNA MIR4300HG rs11232965…”

The Life Cycle of the Mu-Opioid Receptor

“…Numerous groups have also investigated the relationship between this polymorphism and postoperative reactions to anaesthesia such as vomiting, nausea, dizziness and pruritus, albeit with some discrepancies [13,14]. As in the case of opioid-induced side effects, there is contradicting data with regards to the effects of this SNP in alcoholism [15], nicotine addiction [16], heroin misuse and relapse [17], and gambling [18]. Interestingly, pain and reward processing are not the only behaviours reported to be affected by the rs1799971 SNP.…”